

# Integrated Filing (Finance) Ind AS

## ORCHID PHARMA LIMITED

### General Information

Scrip code*	524372	
NSE Symbol*	ORCHPHARMA	
MSEI Symbol*	NOTLISTED	
ISIN*	INE191A01027	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	11-02-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	06-02-2026	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Third quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited	
Segment Reporting	Single segment	
Description of single segment	PHARMACEUTICALS	
Start date of board meeting	11-02-2026	
Start time of board meeting	13:30:00	
End date of board meeting	11-02-2026	
End time of board meeting	17:15:00	
Whether cash flow statement is applicable on company		
Type of cash flow statement		
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	true	
No. of times funds raised during the quarter	1	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	false	<a href="#">Textual Information(1)</a>

## Text Block

<a href="#">Textual Information(1)</a>	Not Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period.
--	---

## Financial Results - Ind-AS

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm- yyyy)	Year to date figures for current period ended (dd-mm- yyyy)
Date of start of reporting period	01-10- 2025	01-04- 2025
Date of end of reporting period	31-12- 2025	31-12- 2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Part I	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>	
<b>1</b>	<b>Income</b>	
	Revenue from operations	20,726.70    57,372.00
	Other income	1,059.00    4,194.56
	<b>Total income</b>	<b>21,785.70    61,566.56</b>
<b>2</b>	<b>Expenses</b>	
(a)	Cost of materials consumed	11,896.58    34,139.09
(b)	Purchases of stock-in-trade	25.00    121.13
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,393.08    3,191.63
(d)	Employee benefit expense	2,288.38    6,854.36
(e)	Finance costs	316.91    1,015.89
(f)	Depreciation, depletion and amortisation expense	896.79    2,641.33
(g)	<b>Other Expenses</b>	
1	Other expenses	3,840.12    11,431.44
	<b>Total other expenses</b>	<b>3,840.12    11,431.44</b>
	<b>Total expenses</b>	<b>21,656.86    59,394.87</b>
<b>3</b>	<b>Total profit before exceptional items and tax</b>	
	128.84	2,171.69
4	Exceptional items	(711.27)    (711.27)
<b>5</b>	<b>Total profit before tax</b>	
	(582.43)	1,460.42
<b>6</b>	<b>Tax expense</b>	
7	Current tax	0.00    0.00
8	Deferred tax	0.00    0.00
<b>9</b>	<b>Total tax expenses</b>	
	0.00	0.00
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00    0.00
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>	
	(582.43)	1,460.42
12	Profit (loss) from discontinued operations before tax	0.00    0.00
13	Tax expense of discontinued operations	0.00    0.00
<b>14</b>	<b>Net profit (loss) from discontinued operation after tax</b>	
	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00    0.00

16	<b>Total profit (loss) for period</b>	(582.43)	1,460.42
17	Other comprehensive income net of taxes	56.42	1.49
18	<b>Total Comprehensive Income for the period</b>	(526.01)	1,461.91
19	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	<b>Details of equity share capital</b>		
	Paid-up equity share capital	5,071.91	5,071.91
	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		
23	<b>Earnings per share</b>		
i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	(1.15)	2.88
	Diluted earnings (loss) per share from continuing operations	(1.15)	2.88
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	(1.15)	2.88
	Diluted earnings (loss) per share from continuing and discontinued operations	(1.15)	2.88
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	<a href="#">Textual Information(1)</a>	

## Text Block

<a href="#">Textual Information(1)</a>	<p>1. The above results for the quarter and nine months period ended December 31, 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on February 11, 2026. The statutory auditors of the company have expressed a modified conclusion on the Limited review. ' ' 2. The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. ' ' 3. The Government of India has consolidated the multiple existing labour legislations into a unified framework comprising of Labour Codes collectively referred to as New 'Labour Codes' which become effective from 21 November 2025. The company has reassessed the employee benefits obligations in accordance with the revised definition of wages. Accordingly, based on management assessment and actuarial valuation, an incremental liability on account of past service cost in accordance with IND AS 19 'Employee Benefits' amounting to Rs. 711.271 lakhs has been shown under exceptional items in the Statement of Profit and Loss for the quarter and nine months ended December 31, 2025. Further in view of the relevant Rules yet to be notified, the company would continue to monitor developments relating to the implementation of the New Labour Codes and will review its estimates and assumptions on an ongoing basis. ' ' 4. 99,02,705 fully paid up Equity Shares of face value Rs.10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. ' As on December 31, 2025 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below :Statement of aIP Net Funds raised and utilisation is furnished below: ' ' Statement of QIP Net Funds raised and utilisation ' Particulars Amount as stated in Total amount utilised Balance amount as on Remarks ' the Offer Document upto December 31, 2025 on December 31, 2025 kept ' (Rs. In Lakhs), (revised) (Rs. In Lakhs) in Fixed Deposits (Rs. in lakhs) ' 1. Investment in OBPL, ' subsidiary, for setting up ' Jammu Manufacturing Facility 13500 7302 6198 ' 2. Repayment/prepayment, in ' full or in part, of certain ' outstanding borrowings ' availed by the company 19546 19546 - ' 3. Funding capital expenditure ' requirements for setting up a ' new block at the API facility ' of the Company in Alathur, ' Tamil Nadu 36 36 0 ' 4. General corporate purposes 6372 6372 0 ' Total 39454 33256 6198 ' ' ' #As per</p>
--	--

the QIP offer document the amount allocated for General Corporate Purpose (GCP) was Rs.6098 Lakhs which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the surplus amount of Rs.274 Lakhs has been included in the GCP amount allocated/ utilized as on 31st December, 2025. The Allocation among the objects has been revised vide Shareholder's resolution dated September 20, 2025.

5. Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits.

6. The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable.

7. The Company has submitted a petition with the Hon'ble National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited ("the Amalgamating Company") with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013. The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation letter from the BSE Limited and National Stock Exchange of India Limited ("stock exchanges") giving No objection to the said amalgamation. The requisite approvals of the concerned shareholders and creditors, as directed by the Hon'ble NCLT have been duly secured. Further, the Companies submitted the Joint Company Petition seeking approval on the Scheme of Amalgamation. During the hearing held on February 04, 2026, Office of Official Liquidator and Regional Director confirmed the submission of their respective reports. Pursuant thereto, the Hon'ble NCLT directed verification and adjourned to the next hearing scheduled for March 02, 2026.

8. Figures of the previous period have been regrouped/reclassified/restated wherever considered necessary.

## Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm- yyyy)	Year to date figures for current period ended (dd-mm- yyyy)
Date of start of reporting period	01-10- 2025	01-04- 2025
Date of end of reporting period	31-12- 2025	31-12- 2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
<b>Other comprehensive income [Abstract]</b>		
<b>1 Amount of items that will not be reclassified to profit and loss</b>		
1 Items that will not be reclassified to profit And loss	56.42	1.49
Total Amount of items that will not be reclassified to profit and loss	56.42	1.49
2 Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
<b>3 Amount of items that will be reclassified to profit and loss</b>		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss		
5 Total Other comprehensive income	56.42	1.49

## Audit qualification

Sr.	Details of Audit Qualification	Type of Audit Qualification	Frequency of qualification	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s) where the impact is not quantified by the auditor		
				Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditor Comment on (i) or (ii) above
No records available							

## Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising	QIP
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	27-06-2023
Amount Raised	40,000.00
Report filed for Quarter ended	31-12-2025
Monitoring Agency	true
Monitoring Agency Name, if applicable	Care Ratings Limited
Is there a Deviation / Variation in use of funds raised	true
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	true
If Yes, Date of shareholder Approval	20-09-2025
Explanation for the Deviation / Variation	<p>In view of changes in the business environment and to meet current strategic requirements, the Company has modified the allocation of the QIP Proceeds. The commencement of "new block at API Facility of the Company in Alathur" project has been postponed to a later stage. Therefore, QIP Proceeds allotted to API Facility in Alathur has been reallocated with the approval of shareholders at the AGM held on September 30, 2025, to mitigate such additional financial burden, improve profit and ensure the best possible utilization of the QIP proceeds in the overall interest of the Company and its shareholders.</p>
Comments of the Audit Committee after review	<p>The reallocation approved by the Shareholders had been reviewed by the Audit Committee and recommended in the overall interest</p>

of the Company.  
With respect to the  
comments by  
Monitoring Agency  
in Monitoring  
Agency Report,  
remark and  
comment in give  
hereunder:

Remark 1: Delay in  
implementation of  
the object(s) w.r.t  
the object-  
Funding capital  
expenditure  
requirements for  
setting up a new  
block at the API  
Facility of the  
Company in  
Alathur, Tamil  
Nadu but the  
extent of delay is  
not ascertainable.

Comment: Entire  
amount allotted as  
per the revised  
object schedule  
(Rs 36 lakhs) was  
utilized as of June  
30, 2025. Hence  
no amount  
remained  
unutilised. Remark

2: Delay in  
implementation of  
the object(s) w.r.t  
the object-  
Investment in  
OBPL for setting  
up Jammu  
Manufacturing  
Facility but the  
extent of delay is  
not ascertainable.

Comment: The  
Land of around  
203.8 Kanal  
(25.475 acres) at  
Jammu had been  
identified, out of  
which registration  
of 176.65 Kanal of  
land has  
completed and  
registration of the  
remaining land  
parcel is expect to  
be completed upto  
March 2026.

Construction of  
boundary had  
been completed  
and construction  
activity of Major  
Building is in  
advance stage.  
Installation of  
equipment's  
already started.  
The Land

	acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Further for this land Change of Land Use (CLU) / registration was required. This has led to delay in acquiring land.
Comments of the auditors, if any	Nil

Objects for which funds have been raised and where there has been a deviation, in the following table:

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in Jammu	Not Applicable	9,000.00	13,500.00	7,302.00	0.00	<a href="#">Textual Information(1)</a>
2	Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our Company	Not Applicable	14,100.00	19,546.00	19,546.00	0.00	<a href="#">Textual Information(2)</a>
3	Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	Not Applicable	9,982.00	36.00	36.00	0.00	<a href="#">Textual Information(3)</a>
4	General corporate purposes	Not Applicable	6,098.00	6,372.00	6,372.00	0.00	<a href="#">Textual Information(4)</a>

## Text Block

<a href="#">Textual Information(1)</a>	Allocation among the object has been revised vide AGM resolution dated September 20, 2025 to Rs.135 Lakh by allotting Rs. 45 crores from capital expenditure for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu.
<a href="#">Textual Information(2)</a>	Allocation of Rs.54.46 Crores from Fund raised for API Facility at Alathur.  The Company has transferred Rs. 54.56 crores from MA account to CC account towards repayment of working capital borrowings.
<a href="#">Textual Information(3)</a>	Allocated the Funds to other objects of the QIP with the approval of shareholders.
<a href="#">Textual Information(4)</a>	Nil

## Signatory Details

Name of signatory	Kapil Dayya
Designation of person	Company Secretary and Compliance Officer
Place	Gurugram
Date	11-02-2026